Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure

Health Policy

Volumn 121, Issue 4, 2017, Pages 363-377

  Gourzoulidis, George ^a   Kourlaba, Georgia ^b   Stafylas, Panagiotis ^c   Giamouzis, Gregory ^d   Parissis, John ^e   Maniadakis, Nikolaos ^f  

^a EVROSTON LP   (Greece)

^b Non Profit Civil Partenrship ^*  (Greece)

^c Medical Research and Innovation LP   (Greece)

^d UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^f NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

Author keywords

Chronic diseases; Copay; Cost sharing; dherence

Indexed keywords

ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT;

CHRONIC DISEASE; DIABETES MELLITUS; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEART FAILURE; HUMAN; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; REVIEW; SYSTEMATIC REVIEW; COST; ECONOMICS; OUTCOME ASSESSMENT;

CHRONIC DISEASE; COST SHARING; DIABETES MELLITUS; DRUG COSTS; HEALTH CARE COSTS; HEART FAILURE; HUMANS; MEDICATION ADHERENCE; PATIENT OUTCOME ASSESSMENT;

EID: 85016492834     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2017.02.008     Document Type: Review

References (85)

1. [1] Organization of Economic Cooperation and Development (OECD), Health at a glance 2011. 2011, OECD INDICATORS Available from: http://www.oecd.org/els/health-systems/49105858.pdf [Accessed 30 September 2015].
2. [2] Barnieh, L., Clement, F., Harris, A., Blom, M., Donaldson, C., Klarenbach, S., et al. A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development. PLoS One, 9(3), 2014, e90434.
3. [3] Thomson, S., Foubister, T., Figueras, J., Kutzin, J., Permanand, G., Bryndova, L., Addressing financial sustainability in health systems. 2009 Available from: http://www.euro.who.int/__data/assets/pdf_file/0005/64949/E93058.pdf [Accessed 30 September 2015].
4. [4] Karampli, E., Souliotis, K., Polyzos, N., Kyriopoulos, J., Chatzaki, E., Pharmaceutical innovation: impact on expenditure and outcomes and subsequent challenges for pharmaceutical policy, with a special reference to Greece. Hippokratia 18:2 (2014), 100–106.
5. [5] Foundation for Economic and Industrial Research (IOBE), The pharmaceutical market in Greece: facts and figures 2013. 2014 Available from: http://iobe.gr/docs/research/en/RES_05_A_03122014_REP_ENG.pdf [Accessed 28 September 2015].
6. [6] Espin, J., Rovira, J., 2007. Analysis of differences and commonalities in pricing and reimbursement systems in Europe, Final Report European Commission June 2007. Editor.
7. [7] Drummond, M., Towse, A., Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?. The European Journal of Health Economics 13:1 (2012), 1–5.
8. [8] Vogler, S., Zimmermann, N., Leopold, C., de Joncheere, K., Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Review 4:2 (2011), 69–79.
9. [9] Economou C, K.D., Kentikelenis A, Sissouras A, Maresso A., The Impact of the Financial Crisis on the Health System and Health in Greece. Economic Crisis, Health Systems and Health in Europe: Country Experience, C.W.E.O.o.H.S.a. Policies, Editor. 2014.
10. [10] Sinnott, S.J., Buckley, C., O'Riordan, D., Bradley, C., Whelton, H., The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLoS One, 8(5), 2013, e64914.
11. [11] Eaddy, M.T., Cook, C.L., O'Day, K., Burch, S.P., Cantrell, C.R., How patient cost-sharing trends affect adherence and outcomes: a literature review. Pharmacy and Therapeutics P&T 37:1 (2012), 45–55.
12. [12] Goldman, D.P., Joyce, G.F., Zheng, Y., Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298:1 (2007), 61–69.
13. [13] Mann, B.S., Barnieh, L., Tang, K., Campbell, D.J., Clement, F., Hemmelgarn, B., et al. Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review. PLoS One, 9(3), 2014, e89168.
14. [14] Atella, V., Peracchi, F., Depalo, D., Rossetti, C., Drug compliance, co-payment and health outcomes: evidence from a panel of Italian patients. Health Economics 15:9 (2006), 875–892.
15. [15] Cohen, J., Christensen, K., Feldman, L., Disease management and medication compliance. Population Health Management 15:1 (2012), 20–28.
16. [16] Mueller, C., Schur, C., O'Connell, J., Prescription drug spending: the impact of age and chronic disease status. American Journal of Public Health 87:10 (1997), 1626–1629.
17. [17] Mojtabai, R., Olfson, M., Medication costs, adherence, and health outcomes among Medicare beneficiaries. Health Affairs (Millwood) 22:4 (2003), 220–229.
18. [18] Heisler, M., Choi, H., Rosen, A.B., Vijan, S., Kabeto, M., Langa, K.M., et al. Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis. Medical Care 48:2 (2010), 87–94.
19. [19] Piette, J.D., Heisler, M., Wagner, T.H., Cost-related medication underuse: do patients with chronic illnesses tell their doctors?. Archives of Internal Medicine 164:16 (2004), 1749–1755.
20. [20] Soumerai, S.B., Pierre-Jacques, M., Zhang, F., Ross-Degnan, D., Adams, A.S., Gurwitz, J., et al. Cost-related medication nonadherence among elderly and disabled medicare beneficiaries: a national survey 1 year before the medicare drug benefit. Archives of Internal Medicine 166:17 (2006), 1829–1835.
21. [21] Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131:4 (2015), e29–e322.
22. [22] Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 87:1 (2010), 4–14.
23. [23] Cleland, J.G., Swedberg, K., Follath, F., Komajda, M., Cohen-Solal, A., Aguilar, J.C., et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. European Heart Journal 24:5 (2003), 442–463.
24. [24] Giamouzis, G., Triposkiadis, F., Georgiopoulou, V.V., Farmakis, D., Westermann, D., Skoularigis, J., Heart failure 2013. Cardiology Research and Practice, 2013, 2013, 342316.
25. [25] Zannad, F., Agrinier, N., Alla, F., Heart failure burden and therapy. Europace 11:Suppl. 5 (2009), v1–v9.
26. [26] Heidenreich, P.A., Albert, N.M., Allen, L.A., Bluemke, D.A., Butler, J., Fonarow, G.C., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation: Heart Failure 6:3 (2013), 606–619.
27. [27] Filippatos, G., Farmakis, D., Bistola, V., Karavidas, A., Mebazaa, A., Maggioni, A.P., et al. Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot survey. European Heart Journal: Acute Cardiovascular Care, 2014.
28. [28] Parissis, J., Athanasakis, K., Farmakis, D., Boubouchairopoulou, N., Mareti, C., Bistola, V., et al. Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital. International Journal of Cardiology 180 (2015), 46–49.
29. [29] Stewart, S., Jenkins, A., Buchan, S., McGuire, A., Capewell, S., McMurray, J.J., The current cost of heart failure to the National Health Service in the UK. European Journal of Heart Failure 4:3 (2002), 361–371.
30. [30] Cook, C., Cole, G., Asaria, P., Jabbour, R., Francis, D.P., The annual global economic burden of heart failure. International Journal of Cardiology 171:3 (2014), 368–376.
31. [31] Lee, W.C., Chavez, Y.E., Baker, T., Luce, B.R., Economic burden of heart failure: a summary of recent literature. Heart & Lung 33:6 (2004), 362–371.
32. [32] Ambrosy, A.P., Fonarow, G.C., Butler, J., Chioncel, O., Greene, S.J., Vaduganathan, M., et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. Journal of the American College of Cardiology 63:12 (2014), 1123–1133.
33. [33] World Health Organization, Global report on diabetes., 2016 Available from: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1. [Accessed 28 October 2016].
34. [34] Migdalis, I., Rombopoulos, G., Hatzikou, M., Manes, C., Kypraios, N., Tentolouris, N., The cost of managing type 2 diabetes mellitus in Greece: a retrospective analysis of 10-year patient level data the HERCULES study. International Journal of Endocrinology, 2015, 2015, 520759.
35. [35] Kanavos, P., van den Aardweg, Stacey, Schurer, Willemien, Diabetes expenditure, burden of disease and management in 5 EU countries., 2012 Available from: http://www.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/LSEDiabetesReport26Jan2012.pdf. [Accessed 30 September 2015].
36. [36] da Rocha Fernandes, J., Ogurtsova, K., Linnenkamp, U., Guariguata, L., Seuring, T., Zhang, P., et al. IDF diabetes atlas estimates of 2014 global health expenditures on diabetes. Diabetes Research and Clinical Practice 117 (2016), 48–54.
37. [37] Seuring, T., Archangelidi, O., Suhrcke, M., The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics 33:8 (2015), 811–831.
38. [38] Nichols, G.A., Gullion, C.M., Koro, C.E., Ephross, S.A., Brown, J.B., The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:8 (2004), 1879–1884.
39. [39] Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 62:10 (2009), e1–e34.
40. [40] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 62:10 (2009), 1006–1012.
41. [41] Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies. 2010. Available from: http://www.ephpp.ca/PDF/Quality%20Assessment%20Tool_2010_2. [Accessed September 30 2016].
42. [42] Cole, J.A., Norman, H., Weatherby, L.B., Walker, A.M., Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy 26:8 (2006), 1157–1164.
43. [43] Babazono, A., Miyazaki, M., Imatoh, T., Une, H., Yamamoto, E., Tsuda, T., et al. Effects of the increase in co-payments from 20 to 30 percent on the compliance rate of patients with hypertension or diabetes mellitus in the employed health insurance system. International Journal of Technology Assessment in Health Care 21:2 (2005), 228–233.
44. [44] Barron, J., Wahl, P., Fisher, M., Plauschinat, C., Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications. Pharmacy and Therapeutics P&T 33:9 (2008), 532–553.
45. [45] Colombi, A.M., Yu-Isenberg, K., Priest, J., The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. Journal of Occupational & Environmental Medicine 50:5 (2008), 535–541.
46. [46] Hunt, J., Rozenfeld, Y., Shenolikar, R., Effect of patient medication cost share on adherence and glycemic control. Managed Care 18:7 (2009), 47–53.
47. [47] Nair, K.V., Miller, K., Saseen, J., Wolfe, P., Allen, R.R., Park, J., Prescription copay reduction program for diabetic employees: impact on medication compliance and healthcare costs and utilization. American Health & Drug Benefits 2:1 (2009), 14–24.
48. [48] Chernew, M., Gibson, T.B., Yu-Isenberg, K., Sokol, M.C., Rosen, A.B., Fendrick, A.M., Effects of increased patient cost sharing on socioeconomic disparities in health care. The Journal of General Internal Medicine 23:8 (2008), 1131–1136.
49. [49] Patterson, M.E., Blalock, S.J., Smith, A.J., Murray, M.D., Associations between prescription copayment levels and beta-blocker medication adherence in commercially insured heart failure patients 50 years and older. Clinical Therapeutics 33:5 (2011), 608–616.
50. [50] Gibson, T.B., Song, X., Alemayehu, B., Wang, S.S., Waddell, J.L., Bouchard, J.R., et al. Cost sharing, adherence, and health outcomes in patients with diabetes. American Journal of Managed Care 16:8 (2010), 589–600.
51. [51] Maciejewski, M.L., Bryson, C.L., Perkins, M., Blough, D.K., Cunningham, F.E., Fortney, J.C., et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. American Journal of Managed Care 16:1 (2010), e20–e34.
52. [52] Maciejewski, M.L., Farley, J.F., Parker, J., Wansink, D., Copayment reductions generate greater medication adherence in targeted patients. Health Affairs (Millwood) 29:11 (2010), 2002–2008.
53. [53] Chui, M.A., Deer, M., Bennett, S.J., Tu, W., Oury, S., Brater, C., et al. Association between adherence to diuretic therapy and health care utilization in patients with heart failure. Pharmacotherapy 23:3 (2003), 326–332.
54. [54] Dragomir, A., Cote, R., White, M., Lalonde, L., Blais, L., Berard, A., et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value in Health 13:1 (2010), 87–94.
55. [55] Esposito, D., Bagchi, A.D., Verdier, J.M., Bencio, D.S., Kim, M.S., Medicaid beneficiaries with congestive heart failure: association of medication adherence with healthcare use and costs. American Journal of Managed Care 15:7 (2009), 437–445.
56. [56] Fitzgerald, A.A., Powers, J.D., Ho, P.M., Maddox, T.M., Peterson, P.N., Allen, L.A., et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. Journal of Cardiac Failure 17:8 (2011), 664–669.
57. [57] Lopert, R., Shoemaker, J.S., Davidoff, A., Shaffer, T., Abdulhalim, A.M., Lloyd, J., et al. Medication adherence and medicare expenditure among beneficiaries with heart failure. American Journal of Managed Care 18:9 (2012), 556–a567.
58. [58] Mockler, M., O'Loughlin, C., Murphy, N., Ryder, M., Conlon, C., McDonald, K.M., et al. Causes and consequences of nonpersistence with heart failure medication. American Journal of Cardiology 103:6 (2009), 834–838.
59. [59] An, S.Y., Kim, H.J., Chun, K.H., Kim, T.H., Jeon, J.Y., Kim, D.J., et al. Clinical and economic outcomes in medication-adherent and -nonadherent patients with type 2 diabetes mellitus in the republic of Korea. Clinical Therapeutics 36:2 (2014), 245–254.
60. [60] Ayyagari, R., Wei, W., Cheng, D., Pan, C., Signorovitch, J., Wu, E.Q., Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment. Value in Health 18:2 (2015), 198–205.
61. [61] Balkrishnan, R., Rajagopalan, R., Camacho, F.T., Huston, S.A., Murray, F.T., Anderson, R.T., Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clinical Therapeutics 25:11 (2003), 2958–2971.
62. [62] Cheng, S.H., Chen, C.C., Tseng, C.H., Does medication adherence lead to lower healthcare expenses for patients with diabetes?. American Journal of Managed Care 19:8 (2013), 662–670.
63. [63] Currie, C.J., Peyrot, M., Morgan, C.L., Poole, C.D., Jenkins-Jones, S., Rubin, R.R., et al. The impact of treatment non-compliance on mortality in people with type 1 diabetes. Journal of Diabetic Complications 27:3 (2013), 219–223.
64. [64] Currie, C.J., Peyrot, M., Morgan, C.L.L., Poole, C.D., Jenkins-Jones, S., Rubin, R.R., et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 35:6 (2012), 1279–1284.
65. [65] Egede, L.E., Gebregziabher, M., Dismuke, C.E., Lynch, C.P., Axon, R.N., Zhao, Y., et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care 35:12 (2012), 2533–2539.
66. [66] Encinosa, W.E., Bernard, D., Dor, A., Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Advances in Health Economics and Health Services Research 22 (2010), 151–173.
67. [67] Hagen, S.E., Wright, D.W., Finch, R., Talamonti, W.J., Edington, D.W., Impact of compliance to oral hypoglycemic agents on short-term disability costs in an employer population. Population Health Management 17:1 (2014), 35–41.
68. [68] Han, E., Suh, D.C., Lee, S.M., Jang, S., The impact of medication adherence on health outcomes for chronic metabolic diseases: a retrospective cohort study. Research in Social and Administrative Pharmacy 10:6 (2014), e87–e98.
69. [69] Hepke, K.L., Martus, M.T., Share, D.A., Costs and utilization associated with pharmaceutical adherence in a diabetic population. American Journal of Managed Care 10:2 Pt. 2 (2004), 144–151.
70. [70] Ho, P.M., Rumsfeld, J.S., Masoudi, F.A., McClure, D.L., Plomondon, M.E., Steiner, J.F., et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Archives of Internal Medicine 166:17 (2006), 1836–1841.
71. [71] Hong, J.S., Kang, H.C., Relationship between oral antihyperglycemic medication adherence and hospitalization, mortality, and healthcare costs in adult ambulatory care patients with type 2 diabetes in South Korea. Medical Care 49:4 (2011), 378–384.
72. [72] Jha, A.K., Aubert, R.E., Yao, J., Teagarden, J.R., Epstein, R.S., Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Affairs (Millwood) 31:8 (2012), 1836–1846.
73. [73] Krapek, K., King, K., Warren, S.S., George, K.G., Caputo, D.A., Mihelich, K., et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Annals of Pharmacotherapy 38:9 (2004), 1357–1362.
74. [74] Martinez, Y.V., Prado-Aguilar, C.A., Rascon-Pacheco, R.A., Valdivia-Martinez, J.J., Quality of life associated with treatment adherence in patients with type 2 diabetes: a cross-sectional study. BMC Health Services Research, 8, 2008, 164.
75. [75] Rhee, M.K., Slocum, W., Ziemer, D.C., Culler, S.D., Cook, C.B., El-Kebbi, I.M., et al. Patient adherence improves glycemic control. Diabetes Educator 31:2 (2005), 240–250.
76. [76] Rozenfeld, Y., Hunt, J.S., Plauschinat, C., Wong, K.S., Oral antidiabetic medication adherence and glycemic control in managed care. American Journal of Managed Care 14:2 (2008), 71–75.
77. [77] Shenolikar, R.A., Balkrishnan, R., Camacho, F.T., Whitmire, J.T., Anderson, R.T., Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clinical Therapeutics 28:8 (2006), 1199–1207.
78. [78] Stuart, B., Davidoff, A., Lopert, R., Shaffer, T., Samantha Shoemaker, J., Lloyd, J., Does medication adherence lower Medicare spending among beneficiaries with diabetes?. Health Services Research 46:4 (2011), 1180–1199.
79. [79] Sokol, M.C., McGuigan, K.A., Verbrugge, R.R., Epstein, R.S., Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care 43:6 (2005), 521–530.
80. [80] Choudhry, N.K., Avorn, J., Glynn, R.J., Antman, E.M., Schneeweiss, S., Toscano, M., et al. Full coverage for preventive medications after myocardial infarction. The New England Journal of Medicine 365:22 (2011), 2088–2097.
81. [81] Goldman, D.P., Joyce, G.F., Escarce, J.J., Pace, J.E., Solomon, M.D., Laouri, M., et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291:19 (2004), 2344–2350.
82. [82] Athanasakis, K., Skroumpelos, A.G., Tsiantou, V., Milona, K., Kyriopoulos, J., Abolishing coinsurance for oral antihyperglycemic agents: effects on social insurance budgets. American Journal of Managed Care 17:2 (2011), 130–135.
83. [83] Keeler, E.B., Brook, R.H., Goldberg, G.A., Kamberg, C.J., Newhouse, J.P., How free care reduced hypertension in the health insurance experiment. JAMA 254:14 (1985), 1926–1931.
84. [84] Clark, D.O., Issues of adherence, penetration, and measurement in physical activity effectiveness studies. Medical Care 39:5 (2001), 409–412.
85. [85] World Health Organization, The world health report 2002—reducing risks, promoting healthy life., 2002 Available from: http://www.who.int/whr/2002/en/whr02_en.pdf?ua=1. [Accessed 27 October 2016].